Hypomanic switch during vortioxetine treatment: a case report

Aydın, Efruz Pirdoğan; Dalkıran, Mihriban; Özer, Ömer; Karamustafalıoğlu, K. Oğuz

doi:10.1080/24750573.2018.1435602

Cited by 11 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinicians should follow this warning and monitor their patients carefully. In addition, we acknowledge the emerging literature pointing towards vortioxetine's potential risks of inducing hypomania, as reported in several case studies 32–37 . The efficacy of vortioxetine for treating pediatric patients with depression has not been confirmed.…”

Section: Discussionmentioning

confidence: 93%

“…In addition, we acknowledge the emerging literature pointing towards vortioxetine's potential risks of inducing hypomania, as reported in several case studies. 32 , 33 , 34 , 35 , 36 , 37 The efficacy of vortioxetine for treating pediatric patients with depression has not been confirmed. Therefore, its use is not approved in the United States or the European Union and is only permitted in Japan after careful consideration.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Vortioxetine as a potential alternative for patients with escitalopram‐induced jitteriness/anxiety syndrome: A report of three cases

Arai,

Nonaka,

Shimada

et al. 2023

PCN Reports

View full text Add to dashboard Cite

BackgroundJitteriness/anxiety syndrome is a recognized adverse effect observed during the initiation or change of dose in antidepressant treatment. Managing patients who develop this syndrome remains a challenge. While escitalopram is a widely used antidepressant known to cause these symptoms, this report explores vortioxetine as a therapeutic alternative.Case PresentationThree distinct clinical scenarios were observed in patients who manifested jitteriness/anxiety syndrome while on escitalopram treatment for depression. Patient A was initiated on escitalopram and experienced an initial alleviation in depressive symptoms, but 3 months later displayed mood elevation, talkativeness, and increased activity, which disturbed his daily life. A transition to vortioxetine subsequently resolved the mood elevation. Patient B exhibited elevated mood, hyperactivity, irritability, and talkativeness just 6 days post‐initiation of treatment with escitalopram. After the discontinuation of escitalopram and unsuccessful trials with aripiprazole, lurasidone, and lamotrigine, her depressive mood intensified, culminating in suicidal ideation. Starting vortioxetine led to a consistent improvement of her symptoms, and she resumed work and was emotionally stable. Patient C was initially diagnosed with bipolar disorder and faced a relapse into depression despite undergoing various treatments. After 2 weeks on escitalopram, she exhibited irritability and self‐harm urges. Three months later, after being re‐diagnosed with depressive disorders with anxious distress, vortioxetine was administered, which significantly reduced her depressive symptoms and allowed her to continue her education.ConclusionVortioxetine presents as a promising therapeutic alternative that is worth considering for patients with escitalopram‐induced jitteriness/anxiety syndrome.

show abstract

Section: Discussionmentioning

confidence: 93%